...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Young Pharmacists >Effectiveness of Second-Line Agents in the Treatment of Uncomplicated Type 2 Diabetes Mellitus: An Observational Tertiary-Care Based Study
【24h】

Effectiveness of Second-Line Agents in the Treatment of Uncomplicated Type 2 Diabetes Mellitus: An Observational Tertiary-Care Based Study

机译：二线药物治疗单纯性2型糖尿病的有效性：基于三级护理的观察性研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: The rational prescribing of second-line drugs in type 2 diabetes mellitus (DM) require clear guidelines. There is no sufficient empirical evidence to support the use of one second-line agent over the other and when to initiate second-line drug is still under discrepancy. Objectives: To analyze the utilization pattern and effectiveness of second-line agents in uncomplicated type 2 DM. Methodology: 240 uncomplicated type 2 DM patients who were ≥ 18 years receiving either metformin/sulfonylurea or metformin+sulfonylurea was divided into four add-on treatment group 1, 2, 3, 4; that were added pioglitazone, dipeptidyl peptidase-4(DPP-4) inhibitor, voglibose, and insulin [pre-mixed insulin (30%regular/70%NPH)] respectively and received the second-line agents for a duration of 6 months or longer. Effectiveness was based on the reduction in glycosylated hemoglobin (HbA1C), fasting plasma glucose (FPG) and postprandial blood glucose (PPBG) values over 3 and 6 months was done using repeated measures analysis of variance (ANOVA). Results: The mean difference for reduction in HbA1C (%) values at 3rd and 6th month with respect to baseline values was 1.32±0.72 and 2.11±0.97; 1.19±0.27 and 1.81±0.53; 1.16±0.41 and 1.66±0.63; 0.97±0.16 and 1.46±0.47 for pioglitazone, DPP-4 inhibitor, voglibose, insulin respectively. The mean difference in FPG and PPBG levels at the 6th month from baseline was 75±31.06 and 115.3±40.32; 77.91±37.95 and 117±41.27; 85.87±21.75 and 118.75±55.86; 91.38±31.8 and 132.03±56.24 for pioglitazone, DPP-4 inhibitors, voglibose and insulin respectively. Reduction in HbA1C, FPG, and PPBG was statistically significant within each group at each time interval with p-value Conclusion: All the add-on groups exhibited a significant reduction in HbA1C, FPG, and PPBG over 3 and 6 months. DPP-4 inhibitors exhibited least hypoglycemic episodes. DPP-4 inhibitors are trending and marginally more effective second-line OHA in uncomplicated type 2 DM.
机译：背景：2型糖尿病（DM）中二线药物的合理处方需要明确的指南。没有足够的经验证据来支持使用一种二线药物而不是另一种，何时开始使用二线药物仍存在差异。目的：分析简单的2型糖尿病患者二线药物的利用模式和有效性。方法：将240名≥18岁且未接受二甲双胍/磺酰脲或二甲双胍+磺酰脲治疗的2型糖尿病患者分为四个附加治疗组：1、2、3、4组。分别加入吡格列酮，二肽基肽酶-4（DPP-4）抑制剂，伏格列波糖和胰岛素[预混胰岛素（30％常规/ 70％NPH）]，并接受二线药物治疗，持续6个月或更长。有效性基于糖化血红蛋白（HbA1C），空腹血糖（FPG）和餐后血糖（PPBG）值在3个月和6个月内的减少，方法是使用重复测量方差分析（ANOVA）。结果：第3个月和第6个月HbA1C（％）值相对于基线值降低的平均差异为1.32±0.72和2.11±0.97; 1.19±0.27和1.81±0.53; 1.16±0.41和1.66±0.63;吡格列酮，DPP-4抑制剂，伏格列波糖，胰岛素分别为0.97±0.16和1.46±0.47。与基线相比，第6个月FPG和PPBG水平的平均差异为75±31.06和115.3±40.32; 77.91±37.95和117±41.27; 85.87±21.75和118.75±55.86;吡格列酮，DPP-4抑制剂，伏格列波糖和胰岛素分别为91.38±31.8和132.03±56.24。在每个时间间隔内，各组中HbA1C，FPG和PPBG的减少在统计学上均具有p值结论：所有附加组在3个月和6个月内均显示HbA1C，FPG和PPBG的显着减少。 DPP-4抑制剂表现出最少的降血糖发作。在不复杂的2型DM中，DPP-4抑制剂正在成为趋势，并且二线OHA的有效性略高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号